Trial Outcomes & Findings for The PROOF Study: The PICC Related Obstruction Of Flow Study (NCT NCT01921114)

NCT ID: NCT01921114

Last Updated: 2019-05-17

Results Overview

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

57 participants

Primary outcome timeframe

10 (+/-3) days and any time there is clinically suspected venous thrombosis (as per standard of care)

Results posted on

2019-05-17

Participant Flow

The study was prematurely terminated and the PI was blinded to study data, and therefore never had access to the data and does not have any information that might help us locate it. Additionally, AngioDynamics' IT team ran a thorough search for any data related to this study and no results were found.

Participant milestones

Participant milestones
Measure
BioFlo™ PICC
BioFlo™ Peripherally Inserted Central Catheter (PICC) BioFlo™ Peripherally Inserted Central Catheter (PICC)
Bard® PowerPICC SOLO2®
Bard® Dual-Lumen PowerPICC SOLO2® Bard® Dual-Lumen PowerPICC SOLO2®
Overall Study
STARTED
0
0
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The PROOF Study: The PICC Related Obstruction Of Flow Study

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 10 (+/-3) days and any time there is clinically suspected venous thrombosis (as per standard of care)

Population: The study was prematurely terminated and the PI was blinded to study data, and therefore never had access to the data and does not have any information that might help us locate it. Additionally, AngioDynamics' IT team ran a thorough search for any data related to this study and no results were found.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 30 days post-insertion

Population: The study was prematurely terminated and the PI was blinded to study data, and therefore never had access to the data and does not have any information that might help us locate it. Additionally, AngioDynamics' IT team ran a thorough search for any data related to this study and no results were found.

Secondary objectives of this study are to investigate: * Incidence of other catheter-related complications, inclusive of catheter occlusion, catheter-related infection, technical failures, and premature catheter removals * Incidence of catheter occlusion (independently from other catheter-related complications)

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 30 days post-insertion

Economic outcomes with respect to medical resource utilization requirements will be compared between the two PICC groups. Only data from US sites will be used for this analysis.

Outcome measures

Outcome data not reported

Adverse Events

BioFlo™ PICC

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Bard® PowerPICC SOLO2®

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Alicia Conway

AngioDynamics

Phone: 774-249-8707

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60